H. Lundbeck (OTCPK:HLUY.Y) - Cotización, noticias y análisis

Resumen de acción HLUY.Y

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.

Acerca de la empresa

HLUY.Y fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	3/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Cotiza un 67.2% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 26.64%

Análisis de riesgos

Los accionistas han sido diluidos sustancialmente en el último año

Alta volatilidad del precio de la acción en los últimos 3 meses

Grandes partidas extraordinarias que afectan a los resultados financieros

Los márgenes de beneficio (6.8%) son inferiores a los del año pasado (12.1%)

Competidores de H. Lundbeck A/S

Organon

NYSE:OGN

US$4.8b

Taisho Pharmaceutical Holdings

OTCPK:TAIP.Y

US$3.9b

Jazz Pharmaceuticals

NasdaqGS:JAZZ

US$6.8b

Corcept Therapeutics

NasdaqCM:CORT

US$2.4b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for H. Lundbeck
Historical stock prices
Current Share Price	kr.22.00
52 Week High	kr.31.55
52 Week Low	kr.10.00
Beta	0
1 Month Change	28.05%
3 Month Change	-5.67%
1 Year Change	-28.71%
3 Year Change	-43.23%
5 Year Change	-63.44%
Change since IPO	3.00%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	HLUY.Y	US Pharmaceuticals	Mercado US
7D	-4.3%	-0.01%	2.0%
1Y	-28.7%	9.5%	22.3%

Rentabilidad vs. Industria: HLUY.Y obtuvo unos resultados inferiores a los del sector US Pharmaceuticals , que el año pasado arrojó un rendimiento del 9.7%.

Rentabilidad vs. Mercado: HLUY.Y obtuvo unos resultados inferiores a los del mercado US, que fue del 19.3% el año pasado.

Volatilidad de los precios

Is HLUY.Y's price volatile compared to industry and market?
HLUY.Y volatility
HLUY.Y Average Weekly Movement	33.7%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de HLUY.Y ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de HLUY.Y ha aumentado de 16% a 34% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1915	5,353	Deborah Dunsire	www.lundbeck.com

Resumen de fundamentos de H. Lundbeck A/S

¿Cómo se comparan los beneficios e ingresos de H. Lundbeck con su capitalización de mercado?
Estadísticas fundamentales de HLUY.Y
Capitalización bursátil	US$4.83b
Beneficios(TTM)	US$154.28m
Ingresos (TTM)	US$2.28b

30.6x

Ratio precio-beneficio (PE)

2.1x

Ratio precio-ventas (PS)

¿Está HLUY.Y sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de HLUY.Y
Ingresos	kr.16.40b
Coste de los ingresos	kr.3.51b
Beneficio bruto	kr.12.89b
Otros gastos	kr.11.78b
Beneficios	kr.1.11b

Últimos beneficios comunicados

Mar 31, 2022

Próxima fecha de beneficios

Aug 17, 2022

Beneficios por acción (BPA)	1.12
Margen bruto	78.59%
Margen de beneficio neto	6.76%
Ratio deuda/patrimonio	32.2%

¿Cómo se ha desempeñado HLUY.Y a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción HLUY.Y

Recompensas

Análisis de riesgos

Competidores de H. Lundbeck A/S

NYSE:OGN

US$4.8b

OTCPK:TAIP.Y

US$3.9b

NasdaqGS:JAZZ

US$6.8b

NasdaqCM:CORT

US$2.4b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Recent updates

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index

H. Lundbeck A/S Common Stock to Be Deleted from OTC Equity

H. Lundbeck A/S Provides Earnings Guidance for the Year 2022

H. Lundbeck A/S Completes Global Phase Iv, Randomized, Comparative Study Exploring the Role of Vortioxetine

H. Lundbeck A/S Appoints Joergornstein as Member of Lundbeck's Executive Management

Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI

H. Lundbeck A/S Proposes Dividend for the Year 2021

EU Commission Approves Vyepti[®] (Eptinezumab) for the Preventive Treatment of Migraine in Adults

Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17

H. Lundbeck A/S Provides Revenue Guidance for the Full Year of Fiscal 2021

H. Lundbeck A/S Announces New Study Finds That Vortioxetine Helps Patients with MDD and Comorbid Generalized Anxiety Disorder

H. Lundbeck A/S Appoints Tarek Samad as Head of Research, Effective on May 1, 2021

H. Lundbeck A/S Announces Resignation of Henrik Andersen from Board

Rigshospitalet and Lundbeck Announce Partnership to Find New Ways to Treat Brain Diseases

Lundbeck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Eptinezumab for the Prevention of Migraine

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2020

H. Lundbeck A/S Revises Earnings Guidance for the Year 2020

OVATION Pharmaceuticals, Inc. acquired Buronil from H. Lundbeck A/S.

H. Lundbeck A/S Presents Positive Data from the Complete Study with Vortioxetine

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de H. Lundbeck A/S

30.6x

2.1x

Beneficios e Ingresos